Merck , known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee , by a vote of 11 to 1 with one. | June 18, 2023
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.